Targeted hyperthermia using magnetite cationic liposomes and an alternating magnetic field in a mouse osteosarcoma model.
We undertook a study of the anti-tumour effects of hyperthermia, delivered via magnetite cationic liposomes (MCLs), on local tumours and lung metastases in a mouse model of osteosarcoma. MCLs were injected into subcutaneous osteosarcomas (LM8) and subjected to an alternating magnetic field which induced a heating effect in MCLs. A control group of mice with tumours received MCLs but were not exposed to an AMF. A further group of mice with tumours were exposed to an AMF but had not been treated with MCLs. The distribution of MCLs and local and lung metastases was evaluated histologically. The weight and volume of local tumours and the number of lung metastases were determined. Expression of heat shock protein 70 was evaluated immunohistologically. Hyperthermia using MCLs effectively heated the targeted tumour to 45 degrees C. The mean weight of the local tumour was significantly suppressed in the hyperthermia group (p = 0.013). The mice subjected to hyperthermia had significantly fewer lung metastases than the control mice (p = 0.005). Heat shock protein 70 was expressed in tumours treated with hyperthermia, but was not found in those tumours not exposed to hyperthermia. The results demonstrate a significant effect of hyperthermia on local tumours and reduces their potential to metastasise to the lung.
Shido
Y
Y
Department of Orthopaedic Surgery Nagoya University Graduate School of Medicine, Nagoya, 466-8550, Japan.
Nishida
Y
Y
Suzuki
Y
Y
Kobayashi
T
T
Ishiguro
N
N
D000818:Animals; D052203:Ferrosoferric Oxide / Q000008:administration & dosage*; D018840:HSP70 Heat-Shock Proteins / Q000378:metabolism; D006979:Hyperthermia, Induced / Q000379:methods*; D008081:Liposomes; D008175:Lung Neoplasms / Q000517:prevention & control / Q000556:secondary; D008297:Male; D053768:Metal Nanoparticles / Q000008:administration & dosage; D051379:Mice; D008809:Mice, Inbred C3H; D009336:Necrosis; D012516:Osteosarcoma / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D012513:Sarcoma, Experimental / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D012881:Skin Temperature
D018840:HSP70 Heat-Shock Proteins; D008081:Liposomes; D052203:Ferrosoferric Oxide